STAT+: Icon acquires HumanFirst to boost support for digital tools in clinical trials
As pharma companies wrestle with how and when to use wearables and other digital technologies…
Category: Medicine
This chemist’s last startup sold for $4 billion. Now investors have poured $173 million into her next act
Jean Cui, a former Pfizer chemist whose last company was sold to Bristol Myers Squibb…
STAT+: Biotech launches with $82 million for Parkinson’s cell therapy
The dream of being able to pluck a cell therapy off of a freezer shelf…
.jpg)
Q&A: A biotech VC leader shares her next big bets
Kristina Burow has a well-trained eye. That’s true of her work at ARCH Venture Partners,…
STAT+: Pfizer is about to make a big push in cancer. Will investors listen?
Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer…
STAT+: A ‘vaccine-like’ version of Wegovy is on the drawing board at Novo Nordisk
LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a…
STAT+: An inside look at PIPEs, the financing trend that has biotech abuzz
Biotech is awash in PIPEs. The numbers behind these privately negotiated purchases of public-company stock…
Amid measles outbreaks, U.K. launches vaccination ad campaign to boost childhood immunizations
LONDON — Facing a growing outbreak of measles, the U.K. on Thursday unveiled an advertising…
Biden ‘continues to be fit for duty,’ his doctor says, after president undergoes annual physical
BETHESDA, Md. — President Joe Biden “continues to be fit for duty,” his doctor wrote Wednesday…
Chikungunya vaccine approved for select groups by CDC advisory panel
In a global first, some travelers and laboratory researchers who are at risk of contracting…
‘Brain fog’ is one of Covid-19’s most daunting symptoms. A new study measures its impact
Of all the lingering symptoms of long Covid, difficulty focusing and thinking, known as brain…
STAT+: White House to hold a listening session on reforming pharmacy benefit managers
In a bid to combat prescription drug costs, the White House will hold a listening…
CDC advisory panel says people 65 and older should get a Covid spring booster shot
An expert panel advising the Centers for Disease Control and Prevention on vaccines on Wednesday…
Beam is trading like it’s 2021
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about the FTC vs. PBMs, FDA adcomm voting and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
Why won’t Medicare deliver food to sick seniors, if it could get them healthy?
WASHINGTON – Some twelve percent of traditional Medicare beneficiaries have heart failure. Roughly a quarter…
Meet the contenders for the STAT Madness 2024 crown. Voting begins March 1
The 64 contestants whose discoveries and innovations have been selected for the 2024 edition of…
Opinion: Medicare Advantage is bad for patients and bad for investors
In 2023, enrollment in Medicare Advantage, the version of Medicare run by private insurers, surpassed…
Q&A: The scientific integrity sleuth taking on the widespread problem of research misconduct
Elisabeth Bik, a microbiologist by training, has become one of the world’s most influential science…
STAT+: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines
One by one, the companies behind Zoloft, Prozac, and Paxil soured on psychiatry. It was…
Cholera vaccine shortage reaches worst point yet, with experts fearing deadly outbreaks
An unprecedented shortage of cholera vaccine has public health experts fearing that a recent surge…
STAT+: FTC says pharmacy benefit managers are stonewalling requests for information
A much-anticipated inquiry by U.S. antitrust regulators into pharmaceutical industry middlemen has been stymied because…
STAT+: Pharmalittle: We’re reading about Congress punts PBM reform, another obesity drug and more
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are…
GSK pill works in uncomplicated gonorrhea
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Obesity drug from Viking Therapeutics hits target in Phase 2 study, raising hopes for a competitor to existing medicines
An obesity medication from Viking Therapeutics succeeded in a Phase 2 clinical study, the company…
STAT+: Experts say scale of Change cyberattack shows risk of centralized claims processing
Change Healthcare’s recent cyberattack has hospitals, doctors’ offices, and pharmacies across the country reeling as…
Opinion: IVF bans like Alabama’s could cost the lives of children already born
When my wife, Laurie, completed her ninth in vitro fertilization cycle in the spring of…
Protocols originally intended to be extra conservative are now heralded as evidence of mifepristone’s risk
Decisions made by the Food and Drug Administration more than 20 years ago have come…
Opinion: Palliative psychiatry offers a new path for some people with serious mental illness
The Canadian surgeon and urologist Balfour Mount is considered the father of palliative care in…
STAT+: MD Anderson tried — and failed — to resolve research credit dispute between two scientists, new documents show
Early last year, MD Anderson Cancer Center leadership had a problem on their hands: a…
STAT+: Congress ditches site-neutral hospital pay policy
WASHINGTON — Congress will not move forward with a controversial policy to equalize certain Medicare…
STAT+: Private equity firm offers $5.8 billion buyout of hospital billing company R1 RCM
R1 RCM, a large publicly traded technology company that helps hospitals and physicians collect money…
STAT+: The quest for psychedelics in the Amazon would push a Harvard botanist to his limits
The Aztecs called it teonanácatl, or “flesh of the Gods.” Some who ate the intoxicating…
STAT+: Congress punts on PBM reform efforts
WASHINGTON — Congress has abandoned its attempt to reform how pharmacy middlemen operate in an…
The FDA isn’t afraid to yank a disappointing drug
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about state moves on drug pricing, an asthma med for kids and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Obesity treatment from Boehringer Ingelheim, Zealand Pharma succeeds in study in liver condition MASH
LONDON — A drug in development as a weight loss treatment succeeded in a Phase…
STAT+: Liver disease MASH is next target for obesity drugs in development
As drugmakers race to join the obesity drug market ignited by the approval of Wegovy…
Opinion: A new Louisiana capital-punishment bill would fundamentally alter physician licensing
After the recent nitrogen gas execution in Alabama of Kenneth Smith, state Attorney General Steve…
Opinion: What STAT readers think about octogenarian presidents
STAT now publishes selected Letters to the Editor received in response to First Opinion essays…
STAT+: Oregon suspends a portion of its drug transparency law found to be unconstitutional
In a victory for the pharmaceutical industry, Oregon officials have suspended a portion of a…
STAT+: Amgen’s rheumatoid arthritis drug Enbrel targeted for first-in-the-nation price limit in Colorado
WASHINGTON — Colorado is pioneering a new way for states to crack down on prescription…
STAT+: UnitedHealth cyberattack cripples pharmacies’ and hospitals’ ability to process insurance claims
Hospitals, pharmacies, and other health care providers are getting stuck in an insurance processing logjam…
STAT+: Pharmalittle: We’re reading about a pharma job slowdown, diet drugs boosting GDP, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Ocular Therapeutix moves in the right direction, and Alnylam tries to calm some nerves
This week, an encouraging turnaround for Ocular Therapeutix, a chat with Alnylam’s CEO defending changes…
What do CEOs owe the world?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Annovis Bio delivers candor on its Parkinson’s study, even if it doesn’t inspire much confidence
Annovis Bio had my biotech bull%^&! meter running red after it made a late change…
As midwife-assisted home births rise, so too do high-risk births outside hospitals
Kay Kay Lineweaver’s first birthing experience in 2021 didn’t go as planned. Her baby was…
STAT+: Stump Pharmalot: An Ask Me Anything with Ed Silverman
In 2023, STAT launched a brand-new home for our subscribers to connect with each other…
STAT+: Clinical notes automation startup Abridge raises $150 million, takes aim at Microsoft Nuance
A Pittsburgh artificial intelligence startup emerging as a challenger to Microsoft’s clinical note taking business…